Newsroom | 23776 results

Sorted by: Latest

Infectious Diseases
-

AN2 Therapeutics to Participate in 9th Annual Evercore Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Wednesday, December 2, 2026 at 8:20am ET and members of management will be available for 1x1 meetin...
-

Alnylam to Webcast Presentations at Upcoming December Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: Piper Sandler 38th Annual Healthcare Conference on Thursday, December 3, 2026, at 8:30 a.m. ET in New York City Citi’s 2026 Global Healthcare Conference on Thursday, December 3, 2026, at 10:20 a.m. ET in Miami A live audio webcast of each presentation will be availabl...
-

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on November 16, 2026, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award...
-

Journal of Independent Medicine Closes 2026 by Challenging Old Assumptions and Rethinking How We Treat the Whole Patient

WASHINGTON--(BUSINESS WIRE)--The Independent Medical Alliance (IMA) today announced the publication of Volume 2, Issue 6 of the Journal of Independent Medicine (JIM), marking the journal’s tenth issue to date and closing its second year with research and perspectives that challenge established assumptions, revisit familiar treatments and emphasize a more individualized approach to patient care. The new issue brings together editorials, reviews, original research and perspectives spanning influe...
-

Post-Election Poll: Voters Want Stronger Vaccination as U.S. Loses Measles Elimination Status

WASHINGTON--(BUSINESS WIRE)--Voters across party lines want stronger vaccination efforts as the U.S. loses its measles elimination status, according to a new bipartisan poll from Echelon Insights and Impact Research. Three in five voters (61%), including half of Republicans, say the country should re-examine its approach and increase measles vaccination to regain that status.The Partnership to Fight Infectious Disease (PFID) commissioned the survey of 1,008 voters in the likely electorate the we...
-

Medicinal Genomics’ One-Reaction Listeria Test Earns AOAC Certification for Whey Powder, Foods, and Surfaces

BEVERLY, Mass.--(BUSINESS WIRE)--Medicinal Genomics’ one-reaction PathoSEEK® Listeria qPCR test earns AOAC certification for whey powder, ready-to-eat meats, spinach, and surfaces....
-

ImmunityBio Named No. 2 Fastest-Growing Technology Company in North America on the 2026 Deloitte Technology Fast 500™

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that it ranked No. 2 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing tech companies in North America, now in its 32nd year. ImmunityBio grew over 47,000% during 2022 to 2025.“Ranking No. 2 on the Deloitte Technology Fast 500 list reflects the Company’s significant growth and the expanding adoption of ANKTIVA® in the U.S. and globally,” said...
-

Zoetis Receives USDA License for Poulvac® Procerta® HVT-ND-ILT Vaccine for Chickens

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced that the U.S. Department of Agriculture (USDA) has licensed Poulvac® Procerta® HVT-ND-ILT, a vector vaccine for chickens. The license marks an important milestone in Zoetis’ continued investment and industry leadership in poultry health, disease protection, and innovation. Poulvac Procerta HVT-ND-ILT brings three disease targets together in one vaccine and expands the tools available to poultry veterinarians and producer...
-

MindWalk annonce les résultats de son assemblée générale annuelle des actionnaires 2026

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (« MindWalk » ou la « Société ») (NASDAQ : HYFT), société spécialisée dans l’IA bio-native, a annoncé aujourd’hui les résultats du scrutin de son assemblée générale annuelle des actionnaires 2026, qui s’est tenue le 17 novembre 2026. Au total, 18 619 753 actions ordinaires étaient représentées par procuration lors de cette assemblée, soit 39,13 % des 47 574 512 actions ordinaires émises et en circulation à la date de référence du 13 octobr...
-

MindWalk Announces Results of 2026 Annual General Meeting of Shareholders

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk" or the "Company") (NASDAQ: HYFT), a Bio-Native AI company, today announced the voting results of its 2026 Annual General Meeting of Shareholders held on November 17, 2026. A total of 18,619,753 common shares were represented by proxy at the meeting, representing 39.13% of the 47,574,512 common shares issued and outstanding as of the October 13, 2026 record date. Shareholders elected Dr. Jennifer L. Bath, Jon Lieber and Kim Remi...